Revenue and net profit grew 5.72% and 12.49% year-over-year, respectively, driven by strong pharmaceutical and expanding alloy businesses. R&D investment rose 20.57%, while the company increased long-term borrowings for capacity expansion and executed multiple equity incentive plans.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.